FABP1 and Hepatic steatosis: In addition, miRNA‐3941, miRNA‐4517 and miRNA‐4672 can reduce the degree of hepatic steatosis through inhibiting the expression of fatty acid binding protein 1 (FABP1), thus delaying the progression of non‐alcoholic fatty liver disease (NAFLD), which is a major catalytic agent of HCC.28, 29 On the other hand, miRNAs also exert crucial roles in regulating the lipid‐metabolizing enzymes through the metabolic‐related transcription factors.